ovarian cancer
Conditions
Interventions
Experimental Group:pamiparib 60 mg BID plus bevacizumab 7.5 mg/kg Q3W
Sponsors
Hunan Provincial Tumor Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years; 2. Understand the research steps and content, and voluntarily sign a written informed consent form; 3. The patient must be histologically or cytologically confirmed high-grade non-mucinous, epithelial ovarian cancer (including fallopian tube cancer or primary peritoneal cancer); 4. Patients with recurrent or metastatic ovarian cancer who have previously received PARPi treatment/maintenance treatment; 5. Have not used Bevacizumab before; 6. According to the RECIST 1.1 standard, the subject must have at least one measurable target lesion (lesions with longest diameter >= 10 mm, or lymph nodes with short diameter >= 15 mm) that can be examined by CT or MRI; 7. Expected survival period >= 3 months; 8. ECOG score 0-1 points.
Exclusion criteria
Exclusion criteria: 1. Have received chemotherapy, biological therapy, immunotherapy, experimental drugs, anti-cancer Chinese patent medicines or Chinese herbal medicines, or have not yet been taken Patients who have fully recovered from the side effects of treatment; 2. The patient had undergone major surgery =2 ventricular arrhythmia occurred within = Grade 2 caused by previous treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Countries
China
Contacts
Public ContactZhang Keqiang
Hunan Provincial Tumor Hospital
Outcome results
None listed